Study ID |
A clearly stated aim |
Inclusion of consecutive patients |
Prospective collection of data |
Endpoints appropriate to the aim of the
study |
Unbiased assessment of
the study endpoint |
Follow-up period appropriate to the aim of the
study |
Loss to follow up less than 5% |
Prospective calculation of the
study size |
Total |
Shitara 2019 |
2 |
2 |
2 |
2 |
0 |
2 |
2 |
2 |
14 |
Cutsem 2023 |
2 |
2 |
2 |
2 |
0 |
2 |
0 |
2 |
12 |
Banerji 2019 |
2 |
2 |
2 |
2 |
0 |
2 |
2 |
2 |
14 |
Peng 2021 |
2 |
2 |
2 |
2 |
0 |
2 |
2 |
2 |
14 |
Zhang2022 |
2 |
2 |
2 |
0 |
0 |
2 |
2 |
0 |
10 |
Yamaguchi 2023 |
2 |
2 |
2 |
2 |
0 |
1 |
2 |
2 |
13 |